Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sovaldi Best-Selling Drug in July-September after May Launch: IMS
November 11, 2015
- Astellas to Acquire US Biotech Ocata Therapeutics for US$379 Million
November 11, 2015
- Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
- Chugai, Kowa Expand Licensing Deal for Deberza
November 11, 2015
- Ethical Dug Sales Climb 7.8% in September: Crecon Report
November 11, 2015
- Fujifilm’s AML Drug Candidate to Enter PI in US
November 11, 2015
- Shionogi, GSK to Independently Develop Jointly Researched Antibiotics
November 10, 2015
- Jardiance Jumps into Top 20 Ranking on Physicians’ Recollection: Anterio
November 10, 2015
- AZ’s Lung Cancer Treatment Gets Priority Review Status in Japan
November 9, 2015
- Half-Year Revenues of 4 Japanese Majors Beat Projections on Buoyant Global Products
November 6, 2015
- Ono Now Has Oncology Sales Force of 180, Eyes Lung Cancer Indication for Opdivo
November 6, 2015
- Nichi-Iko Eyes Generic Production Capacity of 21 Billion Tablets by 2021
November 5, 2015
- AbbVie Files Humira for Non-Infectious Uveitis
November 5, 2015
- Astellas to Transfer Kiyosu Plant Business to MicroBiopharm Japan
November 4, 2015
- Mochida Seeks Japan Approval of Ulcerative Colitis Drug
November 4, 2015
- AbbVie Files Parkinson’s Treatment in Japan
November 4, 2015
- Edoxaban Flounders in US but No Change to FY2017 Biz Targets: Daiichi Sankyo CEO
November 4, 2015
- Mitsubishi Tanabe to Cut Back on Jobs in Japan
November 4, 2015
- Mitsubishi Tanabe Sales Tick Up as Royalty Income Increases
November 4, 2015
- Daiichi Sankyo Recalls Measles, Rubella Vaccines
November 4, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…